OPINION | If Right to Try does little for patients, it certainly helps those politicians promoting it.
OPINION | PBMs want the same thing their clients and consumers want: lower drug prices.
OPINION | It’s time for the insurance industry to come to the table with biopharmaceutical companies.
OPINION | Congress should take a closer look at the relationship that U.S. government agencies have with the IARC.
OPINION | The PHIT Act has the potential to make a healthy and active lifestyle more affordable.
OPINION | Each man’s treatment is unique, so let’s not rule out a test that can help inform his best medical outcomes.
OPINION | Allowing patients to overrule clinicians and have themselves admitted would upend our entire healthcare system.
OPINION | Policymakers should support increased investments in flexible funding programs.
OPINION | The resources exist, but are diverted from patient care.
OPINION | Designing a logical system focused on health rather than saving money creates a system that costs less.